EGFR and non-small cell lung carcinoma: Targeting PAR2 facilitated the effect of gefitinib in EMT, cell proliferation, migration and apoptosis in gefitinib-sensitive and -resistant NSCLC cells through blocking β-arrestin-ERK signaling upon EGFR transactivation.